8-K: Hims & Hers Health, Inc. Reports Explosive First Quarter 2025 Growth, Revenue Up 111%

Hims & Hers Health, Inc. announced a strong first quarter in 2025, with revenue more than doubling and significant increases in net income and adjusted EBITDA.

Summary

• Hims & Hers Health, Inc. reported its first quarter 2025 financial results, showcasing substantial growth.
• Revenue reached $586.0 million, a 111% increase compared to the first quarter of 2024.
• Net income soared to $49.5 million, a significant jump from $11.1 million in the same period last year.
• Adjusted EBITDA reached $91.1 million, compared to $32.3 million in the first quarter of 2024.
• The company's subscriber base grew to 2.4 million, a 38% increase year-over-year.
• Monthly Online Revenue per Average Subscriber increased to $84, up 53% year-over-year.
• Hims & Hers affirmed its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion.
• The company raised its Adjusted EBITDA guidance for 2025 to a range of $295 million to $335 million.
• Long-term targets for 2030 include at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.
• The company launched liraglutide at the end of March, and announced a long-term collaboration with Novo Nordisk to expand affordable access to proven obesity care.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, increased guidance, and ambitious long-term targets. The company's growth strategy and market positioning appear promising, contributing to a very optimistic sentiment.

Positives

• Significant revenue growth of 111% year-over-year indicates strong market demand and effective business strategies.
• Substantial increase in net income and Adjusted EBITDA demonstrates improved profitability and operational efficiency.
• Growth in subscriber base reflects increasing customer adoption and loyalty.
• The increase in Monthly Online Revenue per Average Subscriber indicates successful monetization of the platform.
• Affirmation and raising of full-year guidance suggests management's confidence in continued growth and profitability.
• The company is focused on expanding personalized solutions, with 60% of subscribers on personalized treatments.
• The company is expanding into new specialties, such as low testosterone and menopausal support.
• The company is establishing partnerships to be a best-in-class curator of healthcare services on its platform, such as the collaboration with Novo Nordisk.
• The company is expanding globally, with recent traction in the UK.
• The company has $323 million of cash, cash equivalents, and short-term investments and no debt on its balance sheet.

Negatives

• Gross margin decreased from 82% to 73% year-over-year, primarily due to the strength in GLP-1 customer acquisitions with accelerated adoption of longer cadence SKUs.
• Slower customer acquisition within the Sexual Health specialty at times, as the company reorients its positioning to target and educate a different segment of prospective subscribers.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• The company's ability to comply with the extensive, complex, and evolving legal and regulatory requirements applicable to its business.
• The company's reliance on third-party sources for industry and market data, which may be inaccurate or unreliable.
• The company's ability to manage the transition of subscribers on commercially available dosages of semaglutide to alternatives on either its platform or other platforms by the end of the second quarter.
• The company's ability to continue offering access to certain compounded GLP-1s after the period of FDA enforcement discretion has ended following resolution of the shortage.

Future Outlook

Hims & Hers expects revenue of $2.3 billion to $2.4 billion and Adjusted EBITDA of $295 million to $335 million for the full year 2025. The company also introduced 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.

Management Comments

• Andrew Dudum, co-founder and CEO, stated, 'Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes.'
• Yemi Okupe, CFO, stated, 'Revenue increased 111% year-over-year as we continued to deliver access to more precise, personalized care at scale.'

Industry Context

Hims & Hers is positioning itself as a leader in the telehealth and personalized medicine space, aiming to disrupt the traditional healthcare system by offering convenient, accessible, and customized care. The company's focus on expanding its platform and forming strategic partnerships aligns with the broader trend of healthcare providers seeking to improve patient access and outcomes through digital solutions.

Comparison to Industry Standards

• Teladoc Health, a leading telehealth company, reported revenue growth of 8% year-over-year in its most recent quarter, significantly lower than Hims & Hers' 111% growth.
• Amwell, another telehealth provider, reported revenue growth of 11.5% year-over-year in its most recent quarter, also lower than Hims & Hers' growth.
• GoodRx, a telehealth company focused on prescription drugs, reported revenue growth of 6% year-over-year in its most recent quarter, also lower than Hims & Hers' growth.
• Hims & Hers' Adjusted EBITDA margin of 16% in Q1 2025 is higher than Teladoc Health's Adjusted EBITDA margin of 10.5% in its most recent quarter.
• Hims & Hers' subscriber growth of 38% year-over-year is higher than Teladoc Health's membership growth of 1% year-over-year.

Stakeholder Impact

• Shareholders will likely benefit from the company's strong financial performance and growth prospects.
• Employees may experience increased opportunities for career advancement and development.
• Customers will have access to a wider range of personalized healthcare solutions and services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its improved financial position.

Next Steps

• Continue executing across the company's priorities to position the platform for long-term ambitions in 2030 and beyond.
• Unlock an experience that provides consumers more insight into their health with less friction through at-home lab testing.
• Launch more extensive low testosterone and menopausal support solutions on the platform by year-end.
• Complete the transition of subscribers on commercially available dosages of semaglutide to alternatives on either the company's platform or other platforms by the end of the second quarter.
• Utilize the learnings from specialty-specific marketing achieved over the last 3 quarters to facilitate growth in the company's tenured specialties.
• Adhere to the company's capital allocation framework to achieve both marketing and Adjusted EBITDA leverage in 2025.
• Pursue opportunities across the breadth of personalized solutions, launching the next generation of specialties, elevating the precision & quality of care, evolving toward best-in-class curator of healthcare services, and global expansion.

Key Dates

Keywords

Hims & Hers, Financial Results, Revenue, EBITDA, Subscribers, Telehealth, Personalized Medicine, Weight Loss, GLP-1, Novo Nordisk